Amgen drug shrinks tumors in lung cancer patients with KRAS gene mutation -study | The Business Standard
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
The Business Standard

Tuesday
May 30, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
TUESDAY, MAY 30, 2023
Amgen drug shrinks tumors in lung cancer patients with KRAS gene mutation -study

World+Biz

Reuters
20 September, 2020, 06:35 pm
Last modified: 20 September, 2020, 06:41 pm

Related News

  • The drug invasion undaunted, undeterred
  • Drug kingpin held with record 21.90kg crystal meth in Cox's Bazar
  • Business leaders call for excluding cosmetics from proposed drug Act
  • Canadian province tries decriminalizing drugs to fight overdose crisis
  • 'Drugs enter NE states from Myanmar before smuggled to Bangladesh': Tripura CM

Amgen drug shrinks tumors in lung cancer patients with KRAS gene mutation -study

Out of 59 NSCLC patients, 32% had a partial response to the drug

Reuters
20 September, 2020, 06:35 pm
Last modified: 20 September, 2020, 06:41 pm
File Photo
File Photo

An experimental Amgen Inc drug that targets a specific genetic mutation shrank tumors in 32% of advanced lung cancer patients and 7% of those with colon cancer, according to data from an early-stage trial presented on Sunday.

The median length of time that patients given the drug sotorasib lived before their disease worsened was 6.3 months for lung cancer patients and 4 months for colorectal cancer patients, the company said. Participants in the 129-patient study were followed for a median of 11.7 months.

Patients in the Phase I trial involving several types of cancer were treated with once daily sotorasib. The oral medication is designed to target a mutated form of a gene known as KRAS that occurs in about 13% of non-small cell lung cancers (NSCLC), the most common type of lung cancer.

The KRAS mutation is also found in 1% to 3% of colorectal and other cancers. Sotorasib is part of a growing trend of precision medicines that target gene mutations driving cancer regardless of which organ the disease originated.

Out of 59 NSCLC patients, 32% had a partial response to the drug - tumor shrinkage by at least 30% - and 88% had either a lesser response or stable disease. For the 42 patients with colorectal cancer, 7% had tumor shrinkage and 74% had stable disease.

"These are patients that have very few options," said Gregory Friberg, Amgen's head of oncology global development. "They were on a third or fourth line of therapy."

The company expects by the end of this year to have results from a mid-stage lung cancer trial that could be used to seek US approval of sotorasib.

Analysts are keen to see how rival KRAS drugs, including data expected later this year from Mirati Therapeutics Inc , will stack up against sotorasib.

Researchers, who presented the Amgen data at a virtual meeting of the European Society for Medical Oncology, said responses were also seen with pancreatic, endometrial, and appendix cancers and melanoma.

Adverse side effects occurred in about 12% of trial patients, researchers reported.

Amgen is also testing the drug in combination with other medications, including Merck & Co's immunotherapy Keytruda.

Amgen / Drug / shrink / tumor / lung cancer patients

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Priority on fighting inflation, funding projects
    Priority on fighting inflation, funding projects
  • Private credit growth hits 13-month low in April
    Private credit growth hits 13-month low in April
  • DSA may scare away potential investors: UN special rapporteur
    DSA may scare away potential investors: UN special rapporteur

MOST VIEWED

  • FILE PHOTO: Halime Adam Moussa, a Sudanese refugee who has fled the violence in her country for the second time, walks in line to receive her food portion from World Food Programme (WFP), near the border between Sudan and Chad in Koufroun, Chad, May 9, 2023. REUTERS/Zohra Bensemra
    UN warns more than one million may flee Sudan bloodshed
  • Jensen Huang on May 29.Photographer: I-Hwa Cheng/Bloomberg
    World's most valuable chipmaker Nvidia unveils more AI products after $184 billion rally
  • FILE PHOTO: Japan Self-Defense Forces soldiers walk past a Patriot Advanced Capability-3 (PAC-3) missile unit after Japan's Chief Cabinet Secretary Yoshihide Suga reviews the unit at the Defense Ministry in Tokyo, Japan, October 8, 2017. REUTERS/Kim Kyung-Hoon/File Photo
    Japan puts missile defences on alert as North Korea warns of satellite launch
  • This file photo shows some of about 1,000 huge tanks holding treated but still radioactive wastewater at the Fukushima Daiichi nuclear power plant, operated by Tokyo Electric Power Company Holdings (TEPCO), in Okuma town, northeastern Japan, on Feb. 22, 2023. Photo: AP
    IAEA team in Japan for final review before planned discharge of Fukushima nuclear plant water
  • FILE PHOTO: People use fans as they gather in a park amid a heatwave warning in Shanghai, China July 23, 2022. REUTERS/Aly Song
    Shanghai records hottest May day in 100 years with temp soaring at 36.1°C
  • FILE PHOTO: Japan's Prime Minister Fumio Kishida attends a bilateral meeting held by U.N. Secretary General Antonio Guterres (not pictured), on the sideline of the G7 leaders' summit in Hiroshima, western Japan May 21, 2023. REUTERS/Androniki Christodoulou/Pool
    Japan PM Kishida's son to resign as secretary after 'inappropriate' behaviour

Related News

  • The drug invasion undaunted, undeterred
  • Drug kingpin held with record 21.90kg crystal meth in Cox's Bazar
  • Business leaders call for excluding cosmetics from proposed drug Act
  • Canadian province tries decriminalizing drugs to fight overdose crisis
  • 'Drugs enter NE states from Myanmar before smuggled to Bangladesh': Tripura CM

Features

An exquisite symphony of flavours awaits in the heart of Old Dhaka, as this vegetarian ensemble takes centre stage, showcasing the rich heritage of traditional cuisine. Photo: Noor-A-Alam

Jagannath Bhojonaloy: Vegetarianism, the traditional way

16h | Food
Inside Airbus's mega plan to develop the aviation ecosystem in Bangladesh

Inside Airbus's mega plan to develop the aviation ecosystem in Bangladesh

18h | Panorama
How women's purchasing power is altering market dynamics

How women's purchasing power is altering market dynamics

17h | Panorama
Media companies are rushing to capture the youngest market of news consumers in the misplaced hope that this will ensure their survival. Photo: Bloomberg

News firms are too obsessed with wooing the young

17h | Panorama

More Videos from TBS

Erdogan prevails in election test

Erdogan prevails in election test

9h | TBS World
Why AB turns its focus on agri from corporate lending?

Why AB turns its focus on agri from corporate lending?

11h | Corporate Talks
Sword of Tipu Sultan sold in auction

Sword of Tipu Sultan sold in auction

13h | TBS World
Who will be the champion if rain washes out reserve day?

Who will be the champion if rain washes out reserve day?

13h | TBS SPORTS

Most Read

1
End of zero tax!
NBR

End of zero tax!

2
Photo: TBS
Energy

Wind power feeds national grid for first time Friday

3
File Photo: Mohammad Minhaj Uddin/TBS
Bangladesh

Low-cost housing planned for 4 lakh Bangabandhu Shilpa Nagar workers

4
Cenbank prints Tk70,000cr new money in 11 months to support nat'l budget
Budget

Cenbank prints Tk70,000cr new money in 11 months to support nat'l budget

5
File Photo: UNB
Bangladesh

US govt's new visa policy does not bother Bangladesh government: Shahriar Alam

6
Govt to double gain tax on land, flat registration
Budget

Govt to double gain tax on land, flat registration

EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]